物理性质 沸点 530.3±60.0 °C at 760 mmHg闪点 274.5±32.9 °C密度 1.3±0.1 g/cm3pKa: 9.06±0.10(预测)PSA: 72.37LogP: 2.74折射率 1.622蒸汽压 0.0±1.4 mmHg at 25°C溶解性 Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)外观形态 淡黄色至淡黄色固体储存条件 防潮, -20°C 冰箱, 在惰性气其中产品应用 该化合物是一种强力的,有抗钾竞争的酸阻冻剂,它直接抑制了气态H+/K+-ATPASE.在体外,它用PH 6.5时IC50 ~19 NM 等于PH6.5时抑制了聚丙烷气态 H+/ K+/-A+-ATPASE活性H+K+/K+-ATATPS活性活性,以浓度超过0.1 NM-10 ΜM的方式抑制酶,同时表现出高度选择性,即使浓度达到 +/ K+-ATAPTASE,也没有任何抑制.在生物化学实验中,它显示质泵(KIK 3 NM)具有高度的亲近性. 在体内,大鼠口服(0.5-4 MG/KG) 抑制了按剂量剂量分辨核酸分泌;4毫克/千克的剂量完全抑制了和2-DEOXY-D-GLUCOSE-STIMATE SE SECRENURSE . ETURSE-STURSE DO DO DOD DODS SULT EXSULT ANDS AND SUFFER SUPERSULTS LATINGS EXTITS, LAPS PREPD PRESS PISALS PFUTD PHITS PRASS PRIS PREVALD PHOD PH) MINDS PH.
上下游产品 5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-carbaldehyde methylamine ethyl 2-chloro-5-(2-fluorophenyl)-1H-pyrrole-3-carboxylate 5-(2-fluorophenyl)-1H-pyrrole-3-carboxylic acid ethyl ester 合成工艺路线路线简述 16133-25-8 + 1240948-77-9 = 881681-00-1 + 110-17-8 反应条件:1.1 Reagents: Diisopropylethylamine Catalysts: 4-(Dimethylamino)Pyridine Solvents: 1,4-Dioxane; 0 - 10 °C; < 10 °C2.1 Reagents: Hydrogen Catalysts: Nickel Solvents: Acetic Acid,Tetrahydrofuran,Water3.1 Reagents: Sodium Borohydride Solvents: Methanol3.2 Solvents: Dimethylacetamide 标题:An Efficient,Scalable And Eco-Friendly Synthesis Of 4,5-Substituted Pyrrole-3-Carbonitriles By Intramolecular Annulation On Pd/c And Hzsm-5 作者:Chen,Jianchao; Et Al 参考文献:Chemcatchem 日期:2019 卷标:11(7) 页码:1943-1948] 2054536-03-5 + 16133-25-8 = 881681-00-1 反应条件:1.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; 0.5 H,-78 °C1.2 3 H,-78 °C 标题:Novel And Practical Synthesis Of Vonoprazan Fumarate 作者:Yu,Qian-Ying; Et Al 参考文献:Synthetic Communications 日期:2017 卷标:47(12) 页码:1169-1174] 1807642-39-2 = 881681-00-1 + 110-17-8 反应条件:1.1 Reagents: Hydrogen Catalysts: Nickel Solvents: Acetic Acid,Tetrahydrofuran,Water2.1 Reagents: Sodium Borohydride Solvents: Methanol2.2 Solvents: Dimethylacetamide 标题:An Efficient,Scalable And Eco-Friendly Synthesis Of 4,5-Substituted Pyrrole-3-Carbonitriles By Intramolecular Annulation On Pd/c And Hzsm-5 作者:Chen,Jianchao; Et Al 参考文献:Chemcatchem 日期:2019 卷标:11(7) 页码:1943-1948 3-吡啶磺酸置于盐酸,Copper Acetate Monohydrate,草酰氯,叠氮化钾,Rhodium(II) Acetate Dimer,2-氨基苯酚,三苯基膦体系中,用 四氢呋喃,水,1,2-二氯乙烷,乙腈 作为反应溶剂,化学反应生成 沃诺拉赞
参考文献:富马酸伏诺拉生的制备方法
标题:富马酸伏诺拉生的制备方法
摘要:本发明提供了富马酸伏诺拉生的制备方法,包括以下步骤:(1)将式i化合物进行叠氮化反应,得到式ⅱ化合物;(2)将式ⅱ化合物与式ⅲ化合物环化,得到式ⅳ化合物;(3)将式ⅳ化合物与式ⅵ化合物进行缩合反应,得到式ⅶ化合物;(4)式ⅶ化合物用酸脱保护得伏诺拉生游离碱;(5)伏诺拉生游离碱与富马酸成盐得到伏诺拉生富马酸盐.根据本发明的方法合成富马酸伏诺拉生,与现有技术相比,富马酸伏诺拉生的总产率提升到60%以上,产率有了大幅提高.此外,化合物式ⅳ可以用作制备富马酸伏诺拉生的新中间体.
专利信息 专利号:AU-2005249508-A1 优先权日:2004-05-28 标题 :Synthesis of metabolically stable analgesics, pain medications and other agents 专利号:EP-1532139-B1 优先权日:2002-07-30 标题 :Total synthesis of myriaporones 专利号:JP-2006504659-A 优先权日:2002-07-30 标题 :Total synthesis of miriapolone 专利号:JP-2008501036-A 优先权日:2004-05-28 标题 :Metabolic stable analgesics, pain pharmacotherapy and synthesis of other substances 专利号:JP-2012254984-A 优先权日:2004-05-28 标题 :Metabolic stable analgesics, pain pharmacotherapy and synthesis of other substances 专利号:CA-2494532-A1 优先权日:2002-07-30 标 题 :Total synthesis of myriaporones全部 工厂 研发
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告 ✅ COA系统入驻 | 共享模式
主要参考文献 1: Shih CA, Wu DC, Shie CB, Hsu PI. Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review. Microorganisms. 2025 Mar 21;13(4):715. doi: 10.3390/microorganisms13040715. 2: Sun X, Li D, Cui L, Du S, Wang X, Wu N. Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective. Am J Transl Res. 2025 Mar 15;17(3):2067-2075. doi: 10.62347/EWFJ6972. 3: Zhang MM, Wang MD, Yang SY, Hu JQ, Zhu BQ, Wei YK, Zhang CL, Long EW. The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. J Infect Public Health. 2025 Apr 8;18(7):102768. doi: 10.1016/j.jiph.2025.102768. Epub ahead of print.
合成参考文献 摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).